{"entity":{"id":"alan-dandrea","kind":"person","name":"Alan D. D'Andrea","aka":[],"tldr":"Mapped the Fanconi anaemia/BRCA DNA repair pathway and how tumours become resistant to PARP inhibitors.","summary":"Alan D'Andrea's laboratory defined the Fanconi anaemia pathway and its convergence with BRCA1/2 in homologous recombination, and has led the field's understanding of PARP inhibitor resistance mechanisms including restoration of replication fork protection and loss of 53BP1. He directs women's cancers and DNA repair research at Dana-Farber and has translated these findings into trials of ATR and DNA-PK inhibitor combinations.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Andrea%20AD%5BAuthor%5D%20Fanconi%20PARP"}],"tags":["dna-repair","parp","resistance"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["parp-inhibitor","synthetic-lethality-approaches"],"targets":["parp","brca","atr"],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-cancer"],"dependsOn":[],"notes":[],"role":"Director, Susan F. Smith Center for Women's Cancers and Center for DNA Damage and Repair, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["DNA damage response","Fanconi anaemia pathway","PARP inhibitor resistance","Ovarian cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Andrea%20AD%5BAuthor%5D%20Fanconi%20PARP"}],"papers":[{"title":"The Fanconi anaemia/BRCA pathway","journal":"Nature Reviews Cancer","year":2003,"doi":"10.1038/nrc970"},{"title":"Mechanisms and consequences of cancer genome instability: lessons from genome sequencing studies","journal":"Annual Review of Pathology","year":2016}],"orcid":"0000-0001-6168-6294"},"route":"/people/alan-dandrea/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"target":[{"id":"atr","kind":"target","name":"ATR","route":"/targets/atr/"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"}],"journal":[{"id":"nature-reviews-cancer","kind":"journal","name":"Nature Reviews Cancer","route":"/journals/nature-reviews-cancer/"}]}}